Table S3.
Scenario analysis: results of cost-effectiveness analysis using derived AE rates
| Brexpiprazole | Lurasidone | Cariprazine | |
|---|---|---|---|
| Total annual cost per patient (medical + pharmacy costs) | $20,516 | $25,519 | $22,349 |
| Relapses | 0.363 | 0.600 | 0.410 |
| Avoided relapses | 0.637 | 0.400 | 0.590 |
| Hospitalizations | 0.281 | 0.464 | 0.317 |
| Avoided hospitalizations | 0.719 | 0.536 | 0.683 |
| QALYs | 0.698 | 0.624 | 0.684 |
| Change in total cost | $1,833 | $3,170 | Reference |
| Change in avoided relapses | 0.047 | −0.191 | Reference |
| Change in avoided hospitalizations | 0.036 | −0.147 | Reference |
| Change in QALYs | 0.014 | −0.060 | Reference |
| ICER per avoided relapse | Dominant | Dominated | Reference |
| ICER per avoided hospitalization | Dominant | Dominated | Reference |
| ICER per QALY | Dominant | Dominated | Reference |
Abbreviations: AE, adverse event; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.